Cargando…

Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses

Understanding the long-term maintenance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity is critical for predicting protection against reinfection. In an age- and gender-matched cohort of 24 participants, the association of disease severity and early immune responses on the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Balachandran, Harikrishnan, Phetsouphanh, Chansavath, Agapiou, David, Adhikari, Anurag, Rodrigo, Chaturaka, Hammoud, Mohamed, Shrestha, Lok Bahadur, Keoshkerian, Elizabeth, Gupta, Money, Turville, Stuart, Christ, Daniel, King, Cecile, Sasson, Sarah C., Bartlett, Adam, Grubor-Bauk, Branka, Rawlinson, William, Aggarwal, Anupriya, Stella, Alberto Ospina, Klemm, Vera, Mina, Michael M., Post, Jeffrey J., Hudson, Bernard, Gilroy, Nicky, Konecny, Pam, Ahlenstiel, Golo, Dwyer, Dominic E., Sorrell, Tania C., Kelleher, Anthony, Tedla, Nicodemus, Lloyd, Andrew R., Martinello, Marianne, Bull, Rowena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768427/
https://www.ncbi.nlm.nih.gov/pubmed/35090598
http://dx.doi.org/10.1016/j.celrep.2022.110345
Descripción
Sumario:Understanding the long-term maintenance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity is critical for predicting protection against reinfection. In an age- and gender-matched cohort of 24 participants, the association of disease severity and early immune responses on the maintenance of humoral immunity 12 months post-infection is examined. All severely affected participants maintain a stable subset of SARS-CoV-2 receptor-binding domain (RBD)-specific memory B cells (MBCs) and good neutralizing antibody breadth against the majority of the variants of concern, including the Delta variant. Modeling these immune responses against vaccine efficacy data indicate a 45%–76% protection against symptomatic infection (variant dependent). Overall, these findings indicate durable humoral responses in most participants after infection, reasonable protection against reinfection, and implicate baseline antigen-specific CD4+ T cell responses as a predictor of maintenance of antibody neutralization breadth and RBD-specific MBC levels at 12 months post-infection.